DTIL Precision Biosciences Inc stock chart & analysis

Conviction 9HealthcareScan · Fri, Nov 6, 2026

Precision Biosciences Inc (DTIL) closed at $10.60 (+7.40%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 81, RS Rating 98, -6.3% from its 52-week high, +154.3% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).

DTIL$10.60+7.40%

ResistanceSupportVol 14Insider buy

Loading chart…

Precision Biosciences IncBiological Products, (No Diagnostic Substances)www.precisionbiosciences.com ↗

Price10.60

Change+7.40%

Gap-1.52%

Rel volume4.54×

Avg volume429.28K

Avg $ vol3.65M

SMA 207.06

SMA 506.90

SMA 2006.65

Price vs 50+53.41%

Price vs 200+59.13%

MA stackbullish

50/200 cross—

Supertrendup · 7.41

RSI (14)81

MACD hist0.40

MACD cross—

Stoch %K / %D86 / 87

ADX (14)22

+DI / −DI46 / 11

RSI divergence—

MACD divergence—

ATR %7.26%

ADR %8.73%

52w high11.29

52w low3.53

From 52w high-6.29%

Above 52w low+199.72%

New 52w highYes

SqueezeOff

Bollinger width67.47%

%B1.24

Donchian pos87.25%

Donchian high11.29

Donchian low5.72

AVWAP (52w high)9.97

vs AVWAP high+6.15%

AVWAP (52w low)7.19

vs AVWAP low+47.09%

OBV trendUp

Chaikin MF (20)0.18

Today vs 20d4.54×

Avg vol (14d)500.93K

Avg vol (20d)429.28K

Avg $ vol (20d)3.65M

Market cap295.56M

RS Rating98 / 99

RS 3m (vs SPY)+46.69%

RS 6m (vs SPY)+37.88%

RS line new highYes

Trend template7/8

Technical rank97.9

1 week+49.86%

1 month+64.54%

3 months+41.82%

6 months+37.58%

1 year+59.82%

YTD+154.33%

P/E-6.46

P/B5.71

P/S8.63

P/FCF-4.48

EPS-3.56

Div yield—

ROE-88.31%

ROA-37.98%

Debt/Eq0.43

Current10.47

EV/EBITDA-4.66

Gross margin—

Net margin-133.45%

Rev growth-50.12%

EPS growth-737.98%

Price target—

Target upside—

Analyst rating—

Institutional63.55%

Ent. value236.13M

Revenue0

Net income-7.59M

Gross profit—

Free cash flow-65.93M

IndustryBiological Products, (No Diagnostic Substances)

ExchangeNasdaq

Shares out25.8M

Employees66

ListedThu, Mar 28, 2019

Free float24.26M

Float %94.0%

Short interest—

Days to cover—

Short volume50.2%

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction9 / 100

Pattern quality—

Tech rank97.9 / 100

Group rank23 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance7.57

Support5.85

Days since event—

Candle confirm—

Financials as of Wed, Sep 30, 2026 · quarterly.

DTIL technical analysis

Trend

DTIL is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 53.4% above the 50-day ($6.90) and 59.1% above the 200-day ($6.65). ADX(14) at 22 points to a moderate trend. It meets 7 of 8 trend-template criteria.

Momentum

RSI(14) is 81, in overbought territory. The MACD histogram is positive. Its RS Rating of 98 puts its weighted 12-month performance ahead of about 98% of the US market, and its RS line is at a new high.

Volume and volatility

Volume on the latest session ran 4.5× its 20-day average. It trades about $3.7M a day on average. ATR(14) is $0.7678, 7.3% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.18) shows accumulation.

Key levels

The chart pattern's support is $5.85 and its resistance $7.57. The 52-week range is $3.53 to $11.29; price is 6.3% below the high and 199.7% above the low. The VWAP anchored at the 52-week high is $9.97, below price.

Performance

DTIL returned +49.9% (1 week), +64.5% (1 month), +41.8% (3 months), +37.6% (6 months), +59.8% (1 year), +154.3% (year to date).

About Precision Biosciences Inc

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Biological Products, (No Diagnostic Substances) · Listed 2019 · 66 employees

Insider activity

SEC Form 4 transactions in DTIL · open-market 2 buys

Insider	Side	Shares	Value	Traded	Filed
Brown Melinda Director · Common Stock · 2026-09-25	Buy	1.14K	$7K	2026-09-25	2026-09-29
Germano Geno J Director · Common Stock · 2026-09-25	Buy	2.61K	$16K	2026-09-25	2026-09-29
Buehler Kevin Director · Restricted Stock Units · 2026-06-03	Grant	20.98K	$0	2026-06-03	2026-06-05
Frankel Stanley Director · Restricted Stock Units · 2026-06-03	Grant	20.98K	$0	2026-06-03	2026-06-05
Brown Melinda Director · Restricted Stock Units · 2026-06-03	Grant	20.98K	$0	2026-06-03	2026-06-05
Pire Shari Lisa Director · Restricted Stock Units · 2026-06-03	Grant	20.98K	$0	2026-06-03	2026-06-05
Germano Geno J Director · Restricted Stock Units · 2026-06-03	Grant	20.98K	$0	2026-06-03	2026-06-05
SMITH J. JEFFERSON Chief Research Officer · Restricted Stock Units · 2026-06-01	Grant	57.39K	$0	2026-06-01	2026-06-03
Amoroso Michael President and CEO · Restricted Stock Units · 2026-06-01	Grant	573.89K	$0	2026-06-01	2026-06-03
Kelly John Alexander Chief Financial Officer · Restricted Stock Units · 2026-06-01	Grant	193.69K	$0	2026-06-01	2026-06-03

SEC filings

EDGAR filings in DTIL · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.